Endocrinology AI Scribe Playbook: Documenting CGM Time in Range for CPT 95251
Documenting CPT 95251 requires a physician-authored interpretation of at least 72 hours of CGM data that reports sensor wear percentage, time in range...

Endocrinology AI Scribe Playbook: Documenting CGM Time in Range for CPT 95251
Documenting CPT 95251 requires a physician-authored interpretation of at least 72 hours of CGM data that reports sensor wear percentage, time in range (70 to 180 mg/dL), time below and above range, GMI, and glucose variability. The interpretation must then link the identified patterns to a specific therapeutic decision and ICD-10 diagnosis.
CPT 95251 pays for physician interpretation, not the AGP printout
CLINICAL UPDATE 2026: Revised for 2026 CMS CPT G2211 attestation rules, California SB 1120 compliance, and NCCI Modifier 25 bundling criteria.
CPT 95251 describes ambulatory continuous glucose monitoring of interstitial tissue fluid through a subcutaneous sensor for a minimum of 72 hours, with analysis, interpretation, and report. Payers reimburse the cognitive work of the interpreting physician or qualified health professional. They do not reimburse the data download, the device, or the vendor-generated Ambulatory Glucose Profile (AGP) that the sensor platform produces automatically.
This distinction drives most denials. Many clinics attach a Dexcom Clarity or FreeStyle LibreView PDF to the chart, add a one-line statement such as "CGM reviewed, see attached," and submit 95251. When a Medicare Administrative Contractor or commercial payer requests records, the reviewer finds no evidence of independent interpretation. The claim fails because a printout cannot demonstrate physician judgment.
Medical directors should treat 95251 as a diagnostic report, similar in structure to a Holter interpretation. The report needs a defined data window, quality metrics, quantified findings, pattern analysis, and a clinical conclusion. An ambient AI scribe can assemble most of this structure in seconds, but only when the documentation model is built around the consensus metrics rather than free-text narrative.
Clinics new to structured CGM documentation can review specialty-specific note frameworks in the Specialty Clinical Documentation Library, which organizes endocrinology templates by service line and billing code.
Six consensus metrics define a defensible 95251 interpretation
The International Consensus on Time in Range (Battelino et al., Diabetes Care 2019) remains the reference standard that the ADA Standards of Care continues to endorse. Auditors increasingly expect 95251 reports to mirror its core metrics. A defensible interpretation reports each of the following with a numeric value and a comparison to target.
Data sufficiency comes before every other metric
Report sensor wear percentage first. The consensus recommends 14 days of data with at least 70 percent sensor wear (roughly 10 days of usable readings) for reliable pattern interpretation. CPT sets a lower floor of 72 hours. Documenting both the date range and the wear percentage proves the billing threshold was met and that conclusions rest on adequate data.
Time in range carries the primary clinical signal
Time in range (TIR) measures the percentage of readings between 70 and 180 mg/dL. For most adults with type 1 or type 2 diabetes, the target is greater than 70 percent, which corresponds roughly to an A1c of 7 percent. For older or high-risk patients, the target relaxes to greater than 50 percent. Each 10 percent change in TIR is clinically meaningful and should be stated explicitly when trending against a prior report.
Time below range establishes hypoglycemia risk
Time below range (TBR) splits into two tiers. Level 1 hypoglycemia (54 to 69 mg/dL) should stay below 4 percent of readings. Level 2 hypoglycemia (below 54 mg/dL) should stay below 1 percent. For older or high-risk patients, total TBR below 70 mg/dL should stay under 1 percent. TBR findings are the strongest link between CGM data and hypoglycemia diagnosis codes.
Time above range quantifies hyperglycemic burden
Time above range (TAR) also splits into two tiers. Level 1 (181 to 250 mg/dL) plus Level 2 combined should stay below 25 percent. Level 2 (above 250 mg/dL) alone should stay below 5 percent. Reporting both tiers distinguishes a patient with frequent mild postprandial excursions from one with sustained severe hyperglycemia.
GMI and coefficient of variation complete the profile
Glucose Management Indicator (GMI) estimates A1c from mean sensor glucose. Discordance between GMI and laboratory A1c (often 0.5 percent or more) is itself a clinical finding worth documenting, since it may indicate altered red cell turnover, anemia, or hemoglobin variants. Coefficient of variation (CV) at or below 36 percent indicates stable glycemia; values above 36 percent signal elevated hypoglycemia risk and justify regimen review.
Pregnancy targets require a separate template
Pregnant patients with type 1 diabetes use a tighter range of 63 to 140 mg/dL, with a target of greater than 70 percent TIR, TBR below 63 mg/dL under 4 percent, and TBR below 54 mg/dL under 1 percent. An AI scribe must recognize pregnancy status and switch reference targets. Applying standard targets to a pregnant patient produces a clinically misleading report.
The 72-hour floor and monthly limit govern every 95251 claim
Two hard rules apply before clinical content matters. First, the data window must contain at least 72 hours of sensor readings. Second, 95251 may be reported no more than once per month per patient, which most payers enforce as a 30-day interval. Additional reviews within the window, including portal messages that discuss CGM data, are not separately reportable under 95251.
Code selection depends on equipment ownership and service type. CPT 95249 covers patient-owned (personal) CGM startup, including sensor placement, hookup, calibration, training, and printout, and is reported once per period of device use. CPT 95250 covers professional (office-owned) CGM with the same startup components. CPT 95251 is the interpretation code and applies to both personal and professional CGM.
Face-to-face contact is not required for 95251. The interpretation may occur on a date separate from any visit, which matters for G2211 and modifier 25 strategy discussed below. The date of service should be the date the interpretation was completed, not the date the sensor data ended.
Device coverage and interpretation coverage are separate questions. Medicare coverage for the CGM device itself falls under the DME Glucose Monitors LCD (L33822), which since 2023 includes patients on any insulin or with a history of problematic hypoglycemia. Interpretation billing under 95251 requires its own medical necessity, documented in the report itself.
Each CGM parameter maps to a specific audit vulnerability
The table below aligns every required parameter with the documentation standard, the typical audit failure, and the structured field that the Scribing.io Documentation Object Model (DOM) uses to capture it.
CPT 95251 parameters, audit risks, and DOM capture mechanisms | |||
Clinical Parameter | Documentation Requirement | Audit Vulnerability | Scribing.io DOM Mechanism |
|---|---|---|---|
Data window | Explicit start and end dates; minimum 72 hours of readings | Missing dates make the 72-hour threshold unverifiable; claim denied as unsupported | Required date-range field parsed from AGP header; blocks note finalization if under 72 hours |
Sensor wear percentage | Percentage of active sensor time; 70 percent or more for 14-day pattern claims | Conclusions drawn from sparse data appear unsupported on peer review | Wear-time field with automatic low-data flag below 70 percent |
Time in range (70 to 180 mg/dL) | Numeric percentage compared to individualized target | "Glucose well controlled" without a number reads as cloned or templated text | Numeric TIR field paired with target selector (standard, older/high-risk, pregnancy) |
Time below range (Level 1 and Level 2) | Separate percentages for 54 to 69 mg/dL and below 54 mg/dL | Hypoglycemia diagnosis codes lack supporting objective data | Tiered TBR fields that trigger hypoglycemia code suggestions when thresholds are exceeded |
Time above range (Level 1 and Level 2) | Separate percentages for 181 to 250 mg/dL and above 250 mg/dL | Hyperglycemia complication codes unsupported by quantified excursions | Tiered TAR fields linked to the assessment narrative |
GMI and lab A1c | GMI value; comparison to most recent A1c with date | Unexplained discordance suggests incomplete review | GMI field with automatic retrieval of last A1c and discordance prompt at 0.5 percent or more |
Coefficient of variation | CV percentage against the 36 percent threshold | Regimen changes for variability appear unjustified without CV | CV field with instability flag above 36 percent |
Pattern analysis | Time-of-day patterns (nocturnal lows, dawn phenomenon, postprandial peaks) | Absence of patient-specific patterns is the top marker of a non-interpretive report | Pattern block populated from clinician dictation, never auto-generated without review |
Clinical decision | Specific medication, dose, timing, or education change; or explicit rationale for no change | Report without a decision fails medical necessity | Mandatory plan field tied to the interpretation, separate from the E/M plan |
Physician attestation | Signature of interpreting physician or QHP with date of interpretation | Unsigned or scribe-only reports are unbillable | Attestation gate requiring clinician edit confirmation and electronic signature |
ICD-10 specificity links time below range to medical necessity
Diagnosis coding must reflect what the interpretation found. A report showing 7 percent TBR in an insulin-treated type 2 patient, coded only as E11.9 (type 2 diabetes without complications), contradicts itself. The objective data documents hypoglycemia, yet the claim asserts no complication. Auditors notice this mismatch, and so do payer AI review tools.
For that same patient, the stronger pairing is E11.649 (ICD-10-CM), type 2 diabetes mellitus with hypoglycemia without coma, plus Z79.4 (ICD-10-CM), long-term (current) use of insulin. Together these codes connect the quantified TBR finding, the insulin exposure that creates hypoglycemia risk, and the dose adjustment documented in the plan.
Hyperglycemia findings call for different codes. A type 2 patient with TIR of 42 percent and Level 2 TAR of 18 percent may support E11.65 (type 2 diabetes with hyperglycemia). Type 1 patients use the E10 family, such as E10.649 or E10.65. Patients on oral hypoglycemics alone use Z79.84, and those on injectable non-insulin agents use Z79.85.
The AI scribe should suggest codes from data, not decide them. When TBR exceeds threshold, the DOM surfaces E11.649 or E10.649 as a candidate. The clinician confirms that the hypoglycemia is clinically significant and documents it in the assessment. This preserves physician ownership of the diagnosis, which matters for both compliance and the payer review rules described below.
Same-day E/M billing with 95251 decides G2211 eligibility
G2211 is the CMS add-on code for visit complexity inherent to longitudinal care of a single serious or complex condition. Endocrinology is a natural fit: diabetes management with CGM is the definition of an ongoing, continuous relationship. The add-on applies to office and outpatient E/M codes 99202 to 99215.
The modifier 25 interaction is the operational trap. CMS does not pay G2211 when the E/M carries modifier 25, except when the separately reported service is an annual wellness visit, vaccine administration, or a Medicare Part B preventive service. CGM interpretation is none of those. If a coder reflexively appends modifier 25 to the E/M because 95251 appears on the same claim, G2211 is lost.
Check whether modifier 25 is actually required. CPT 95251 carries an XXX global indicator in the Medicare Physician Fee Schedule, meaning it has no global surgical period. Many Medicare contractors do not require modifier 25 on an E/M reported with 95251, though some commercial payers do. Verify current NCCI procedure-to-procedure edits and payer policy before setting a default. The detailed decision logic is covered in Managing Modifier 25 Clinical Revenue Integrity.
Three workflow options protect revenue. First, if your payer does not require modifier 25, bill the E/M with G2211 and 95251 on the same date without the modifier. Second, if modifier 25 is required, consider completing the 95251 interpretation on a separate date (for example, reviewing uploaded data before the visit and signing the report the prior day). Third, if both must occur together under modifier 25, accept that G2211 is not payable and do not submit it.
Separate documentation remains mandatory either way. The E/M note must stand on its own medical decision making, and the 95251 report must stand on its own interpretation. Copying TIR numbers into the E/M assessment and also counting them as the interpretation invites a duplicate-work finding. The DOM keeps these as distinct note sections with distinct plan fields.
G2211 attestation still requires substance. CMS expects the record to show that the practitioner is the continuing focal point for the patient's diabetes care. A short statement such as "I serve as the ongoing endocrinology provider managing this patient's type 1 diabetes and CGM-guided insulin therapy" in the E/M note, supported by visit history, satisfies the intent.
California SB 1120 makes physician-authored rationale the denial defense
California SB 1120, the Physicians Make Decisions Act, took effect January 1, 2025. It prohibits health plans and disability insurers from using artificial intelligence, algorithms, or software to deny, delay, or modify care based on medical necessity without review by a licensed physician or qualified health professional. The determination must consider the individual patient's clinical history and circumstances.
This law changes how documentation functions. When a California payer denies 95251 or a related CGM supply, the denial must reflect human clinical judgment applied to your record. A report containing quantified TBR, a named pattern ("recurrent Level 2 hypoglycemia between 02:00 and 04:00 on 9 of 14 nights"), and a specific basal reduction gives the reviewing physician concrete evidence. A templated report gives that reviewer nothing to weigh.
Appeals become faster and stronger. Under SB 1120, clinics can ask whether a licensed reviewer made the determination and what patient-specific factors were considered. When the original note already lists every consensus metric and a clinical decision, the appeal letter writes itself from the record. Clinics outside California should still adopt this standard because similar payer-AI legislation is advancing in multiple states.
The clinic side carries obligations too. California AB 3030 requires disclosure when generative AI drafts patient clinical communications without clinician review. Internal documentation drafted by an AI scribe and reviewed, edited, and signed by the physician is a different category, but the attestation trail matters. The DOM records clinician edits and signature timestamps so that physician authorship is provable on audit.
Ambient AI scribes must separate interpretation from visit narrative
General ambient scribes fail 95251 for a predictable reason. They summarize the conversation. The visit conversation about CGM is usually informal ("your overnights look low, let's drop the Lantus a bit"), and a narrative summary of that exchange produces an E/M note, not a diagnostic report. The interpretation needs structured numeric fields that the conversation rarely states aloud.
The Scribing.io approach uses two inputs. The first is the AGP data itself, ingested as structured values (wear time, TIR, TBR tiers, TAR tiers, GMI, CV, date range). The second is the clinician's spoken or typed reasoning about patterns and decisions. The Scribing.io Clinical Interface merges these into a discrete 95251 report section, while the visit discussion flows into the separate E/M note.
Pattern language must come from the clinician. The DOM will not auto-generate statements like "nocturnal hypoglycemia pattern identified" from numbers alone, because that would produce identical phrasing across patients and resemble cloned documentation. Instead, it prompts the physician to confirm or dictate the pattern, then records that confirmation. This preserves the patient-specific reasoning that auditors and SB 1120 reviewers look for.
Specialty macros accelerate the repetitive parts. Target sets for standard adults, older or high-risk adults, type 1 pregnancy, and pediatric patients are available among the 1,000+ Specialty Clinical Macros, so the physician selects the population once and the reference thresholds populate correctly.
Example 95251 interpretation structure
The following model report shows the expected density for an insulin-treated type 2 patient:
CGM interpretation, CPT 95251. Data window: January 6 to January 19, 2026 (14 days). Sensor wear: 93 percent. TIR (70 to 180 mg/dL): 58 percent (target greater than 70 percent). TBR Level 1: 5 percent; TBR Level 2: 2 percent (targets under 4 percent and under 1 percent). TAR Level 1: 27 percent; TAR Level 2: 8 percent. Mean glucose 162 mg/dL; GMI 7.2 percent; last lab A1c 7.0 percent (December 12, 2025), concordant. CV 41 percent (above 36 percent threshold).
Pattern analysis identifies recurrent hypoglycemia between 01:00 and 04:00 on 8 of 14 nights, followed by rebound hyperglycemia before breakfast, and postprandial peaks above 250 mg/dL after dinner on most days. Interpretation: basal insulin excess overnight with inadequate prandial coverage at the evening meal; elevated variability increases hypoglycemia risk.
Plan: reduce insulin glargine from 34 to 30 units nightly; add 4 units insulin lispro with dinner; counsel on bedtime snack if glucose below 110 mg/dL; repeat CGM interpretation after next 14-day window. Diagnoses: E11.649, E11.65, Z79.4. Interpreted and signed by the attending endocrinologist.
Caption: every metric, one pattern, one decision, one signature.
Medical directors should audit five fields before claim release
A pre-bill review catches most 95251 defects before they become recoupments. Medical directors can assign this check to a coder or build it into the AI scribe's finalization gate. The five fields below account for the large majority of interpretation denials in endocrinology practices.
Date range and wear time: both present, at least 72 hours of data, wear percentage stated.
All tiered metrics quantified: TIR, both TBR levels, both TAR levels, GMI, and CV with numbers.
Patient-specific pattern statement: time-of-day or meal-related pattern written for this patient.
Clinical decision recorded: a specific change, or explicit rationale for continuing therapy.
Frequency and modifier check: no 95251 in prior 30 days; modifier 25 and G2211 logic applied.
Track three metrics monthly at the practice level. Measure the 95251 denial rate by payer, the percentage of interpretations with all consensus metrics present, and G2211 capture rate on eligible E/M visits. A practice running structured CGM documentation should see near-complete metric capture and a falling denial rate within one or two billing cycles.
Remote data review creates additional revenue opportunities. Because 95251 does not require a visit, clinics can schedule monthly interpretation sessions for patients who upload data between appointments. This supports better glycemic outcomes, since frequent CGM review correlates with improved TIR, and it captures reimbursement for work many endocrinologists already perform unpaid through portal messages.
Compliance training should emphasize one principle: the interpretation is a physician document. The AI scribe structures data and drafts language; the physician reviews, edits, decides, and signs. Clinics that preserve this division gain speed without exposing themselves to authorship or medical necessity challenges.
Frequently asked questions about CGM time in range for CPT 95251
What minimum data does CPT 95251 require?
CPT 95251 requires a minimum of 72 hours of continuous interstitial glucose data plus a documented analysis, interpretation, and report. Best practice follows the International Consensus: review 14 days with at least 70 percent sensor wear, and state the exact wear percentage and date range in the note.
How often can CPT 95251 be billed?
CPT 95251 may be reported once per month per patient, which most payers enforce as a 30-day interval, regardless of how often data is reviewed. Repeated portal reviews within that window are bundled. Track the last interpretation date in the EHR to prevent frequency denials and recoupment.
Which ICD-10 codes best support 95251 medical necessity?
Pair the diabetes code that reflects the documented CGM finding with medication status. For a type 2 patient on insulin with time below range above 4 percent, E11.649 plus Z79.4 links hypoglycemia evidence to therapy. Avoid E11.9 when the interpretation identifies complications or excursions.
Can G2211 be billed on the same day as 95251?
G2211 can accompany an office E/M on the same date as 95251 if the E/M does not carry modifier 25. CMS denies G2211 on modifier 25 claims except with AWVs, vaccine administration, or Part B preventive services. Verify whether your payer actually requires modifier 25 first.
Does an AI scribe draft satisfy the interpretation requirement?
No. An AI scribe can extract AGP metrics and structure the note, but the interpreting physician or qualified health professional must review, edit, and sign the report. Auditors look for patient-specific reasoning and a clinical decision, which only the attesting clinician can supply and authenticate.


